J1555
J1555 – Injection, immune globulin (cuvitru), 100 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 9 NDCs crosswalked per 100 MG $18.147/unit ASP+6%
📋 J1555 summary
J1555 is a HCPCS Level II J-code used to bill immune globulin (cuvitru), 100 mg, billed per 100 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J1555: Cuvitru
Code J1555
Billing unit 100 MG Payment limit $18.147/unit NDC-Crosswalk 9
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ1555
DescriptorInjection, immune globulin (cuvitru), 100 mg
Billing unit100 MG
Payment limit / unit$18.147
Est. ASP / unit$17.120 est.
Mapped NDCs9
Data periodQ3 2026
Last updated2026-08-20
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$18.147
Est. ASP / unit
$17.120 est.
Est. after 2% sequester
$17.784
HCPCS dosage
100 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, immune globulin (cuvitru), 100 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2D1G
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2018-01-01
Date added2018-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J1555 = 100 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J1555 WITH EST. MEDICARE PAY
9 NDCs map to J1555. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($18.147/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00944-2850-01 | CUVITRU Immune Globulin Subcutaneous (Human) 200 mg/mL INJECTION, SOLUTION | Takeda | 1 VIAL, SINGLE-USE in 1 CARTON (0944-2850-... | 200 mg/mL | 10 | $181.47 | — | ● Active | CMS + PDAC |
| 00944-2850-03 | CUVITRU Immune Globulin Subcutaneous (Human) 200 mg/mL INJECTION, SOLUTION | Takeda | 1 VIAL, SINGLE-USE in 1 CARTON (0944-2850-... | 200 mg/mL | 20 | $362.94 | — | ● Active | CMS + PDAC |
| 00944-2850-05 | CUVITRU Immune Globulin Subcutaneous (Human) 200 mg/mL INJECTION, SOLUTION | Takeda | 1 VIAL, SINGLE-USE in 1 CARTON (0944-2850-... | 200 mg/mL | 40 | $725.88 | — | ● Active | CMS + PDAC |
| 00944-2850-07 | CUVITRU Immune Globulin Subcutaneous (Human) 200 mg/mL INJECTION, SOLUTION | Takeda | 1 VIAL, SINGLE-USE in 1 CARTON (0944-2850-... | 200 mg/mL | 80 | $1,451.76 | — | ● Active | CMS + PDAC |
| 00944-2850-09 | CUVITRU Immune Globulin Subcutaneous (Human) 200 mg/mL INJECTION, SOLUTION | Takeda | 1 BOTTLE, GLASS in 1 CARTON (0944-2850-09)... | 200 mg/mL | 100 | $1,814.70 | — | ● Active | CMS + PDAC |
| 00944-2850-02 | CUVITRU (1GM, INNER PACK NDC,PF) 20% | Unknown | — | — | 2 | $36.29 | — | — | PDAC |
| 00944-2850-04 | CUVITRU (2GM, INNER PACK NDC,PF) 20% | Unknown | — | — | 2 | $36.29 | — | — | PDAC |
| 00944-2850-06 | CUVITRU (4GM, INNER PACK NDC,PF) 20% | Unknown | — | — | 2 | $36.29 | — | — | PDAC |
| 00944-2850-08 | CUVITRU (8GM, INNER PACK NDC,PF) 20% | Unknown | — | — | 2 | $36.29 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$31.71M
Claims
4,827
Beneficiaries
1,775
Spend / beneficiary
$17,863.74
Spend / claim
$6,568.91
Trend by period
Where J1555 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #97 of 824
#92
BENLYSTA J0490
$32.83M
#93
TRUXIMA Q5115
$32.81M
#94
VYEPTI J3032
$31.97M
#95
ENVARSUS XR J7503
$31.82M
#96
ARALAST NP* J0256
$31.72M
#97
CUVITRU J1555
$31.71M
#98
NEULASTA ONPRO* J2506
$31.45M
#99
ADSTILADRIN J9029
$31.33M
#100
ZEPZELCA J9223
$31.07M
#101
ARANESP(J0881) J0881
$31.07M
#102
VEGZELMA Q5129
$30.16M
Total claims — #225 of 824
#220
MULTIHANCE A9577
5,179
#221
TRIVISC J7329
5,171
#222
EVEROLIMUS* J7527
5,068
#223
VECTIBIX J9303
5,053
#224
DACOGEN* J0894
4,978
#225
CUVITRU J1555
4,827
#226
TYSABRI J2323
4,821
#227
DOXIL* Q2050
4,593
#228
AMVUTTRA J0225
4,551
#229
OCREVUS J2350
4,531
#230
BENDEKA J9034
4,474
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $31.71M | 1,775 | 4,827 | $17,863.74 | $6,568.91 |
| 2025 (Q1-Q4) | $135.18M | 1,957 | 20,804 | $69,074.76 | $6,497.76 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$138.69M
Medicare paid
$108.64M
Submitted services
8,530,710
Denial rate
3.9%
Allowed / service
$16.93
Submitted charges
$600.01M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J1555
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
9 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J1555 billing FAQ
What is HCPCS code J1555?
J1555 is a HCPCS Level II J-code used to bill Injection, immune globulin (cuvitru), 100 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J1555?
One unit of J1555 represents 100 MG. Report the number of units equal to the dose administered divided by 100 MG.
How many units of J1555 should I bill?
Divide the dose administered by the code's unit size (100 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J1555?
The Medicare Part B payment limit is $18.147 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $17.784 per unit. Payment limits are revised quarterly.
Which NDCs bill under J1555?
9 NDCs currently map to J1555 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J1555 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.